Recursion’s REC-994 Trial Fully Enrolled
We are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule. Our…
News
Alliance to Cure Wins Prestigious Rare Disease Organization Award
On this Rare Disease Day, we are honored to announce the National Organization for Rare Disorders (NORD) has awarded the Alliance to Cure Cavernous Malformation this year’s prestigious Abbey S….
Alliance to Cure Cavernous Malformation Recognizes Thomas Jefferson University Hospitals as a CCM Clinical Center
Thomas Jefferson University Hospitals in Philadelphia, Pennsylvania has been recognized as a designated Clinical Center by the Alliance to Cure Cavernous Malformation for the treatment of cavernous malformations. A cavernous…
Alliance to Cure Cavernous Malformation Recognizes Beth Israel Deaconess Medical Center as a CCM Clinical Center
Beth Israel Deaconess Medical Center has been recognized as a designated Clinical Center by the Alliance to Cure Cavernous Malformation for the treatment of cavernous malformations. A cavernous…
Learn More About Clinical Trials
Learn more about how clinical trials work, check out some Myths vs Facts and get your questions answered with our FAQs. Still have more questions? Reach out at ClinicalTrials@AllianceToCure.org
